Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Yahoo! Finance
conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA Nov. 19, 2025 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend "), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (" Alzheimer's "), bipolar disorder (" BD "), major depressive disorder (" MDD ") and post-traumatic stress disorder (" PTSD "), today announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects. Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 “Lithium in Brain” Study Conducted at Massachusetts General Hospital In collaboration with Massachusetts General Hospital as the clinical trial site, Alzamend is investigating the distinctive characteristics of AL001. The primary objective is to assess how AL001 delivers lithium to the brain compared to marketed lithium salts, e
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General HospitalPR Newswire
- Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $45.00 to $42.00. They now have a "buy" rating on the stock.MarketBeat
ALZN
Analyst Actions
- 9/25/25 - Ascendiant Capital
ALZN
Sec Filings
- 11/18/25 - Form 8-K
- 10/24/25 - Form 4
- 10/14/25 - Form 8-K
- ALZN's page on the SEC website